Significant Improvement In Overall Survival In Patients Who Underwent Autologous Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005

摘要: Abstract 2389 Autologous hematopoietic cell transplantation (autoHCT) is standard therapy for high-risk hematologic disorders and solid tumors. We assessed whether overall survival (OS) at Day 100, which represents early transplant-related mortality (TRM), one year, disease-related later TRM, had changed over time. The study population was derived from patients undergoing 68,404 first autoHCTs between 1994–2005 in US Canadian centers reported to the CIBMTR. Statistical significance measured using P trend 6 time cohorts test OS estimates were stable (slope = 0), increasing (slope>0) or decreasing a priori , are not adjusted any covariates such as age, Karnofsky status, etc. Mortality rates 100 were, general, low all diseases examined improved significantly NHL complete remission (CR) 2/sensitive 1 st relapse, lymphoma primary induction failure (no prior remission) myeloma partial remission. Improvements 1-year seen CR1/sensitive relapse of transplant. has many autoHCT likely reflects improvement supportive care better patient selection. treated during most recent period 2004-5 2–5% with chemotherapy sensitive disease pre-autoHCT. Even transplanted resistant CR), rate only 5% MM 9% HL/NHL patients. Although there still significant decline points, especially CR2/sensitive remission, suggesting need control these – non-Hodgkin lymphoma, HL Hodgkin myeloma, CR Rel PIF failure, sens Disclosures: No relevant conflicts interest declare.